Topical application of tranexamic acid in primary total hip arthroplasty: a randomized double-blind controlled trial.
rct · Level II
Where this comes from
- Record sourced from PubMed, PMID 24793893.
- Also identified by DOI 10.1016/j.arth.2014.03.032.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
So far, studies of topical tranexamic acid (TXA) in total hip arthroplasty (THA) were still lacking and controversial. We conducted this randomized double-blind controlled trial which included 101 patients to assess the effect of a high-dose 3g topical TXA in THA. The results showed that 3g topical TXA could significantly reduce transfusions from 22.4% to 5.7% (P<0.05) without increasing the risk of deep vein thrombosis (DVT), pulmonary embolism (PE) and other complications. In addition, topical TXA significantly reduced total blood loss, reduced drain blood loss, and the drops of HB and HCT in topical TXA group were lower than control group. We concluded that 3g topical TXA was effective and safe in reducing bleeding and transfusions in THA.
Medical subject headings
- Antifibrinolytic Agents
- Arthroplasty, Replacement, Hip
- Postoperative Hemorrhage
- Tranexamic Acid
Anatomy
- hip